Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P16473
UPID:
TSHR_HUMAN
Alternative names:
Thyroid-stimulating hormone receptor
Alternative UPACC:
P16473; A0PJU7; F5GYU5; G3V2A9; Q16503; Q8TB90; Q96GT6; Q9P1V4; Q9ULA3; Q9UPH3
Background:
The Thyrotropin receptor, also known as the Thyroid-stimulating hormone receptor, plays a pivotal role in thyroid cell metabolism. It acts as a receptor for TSH or thyrotropin, and for the heterodimeric glycoprotein hormone thyrostimulin, mediating its activity through G proteins which activate adenylate cyclase.
Therapeutic significance:
Linked to conditions such as Hypothyroidism, congenital, non-goitrous, 1, Familial gestational hyperthyroidism, and Hyperthyroidism, non-autoimmune, the Thyrotropin receptor's involvement in these diseases underscores its potential as a target for therapeutic intervention.